ANDA 77826, held by Teva Parenteral. Fenoldopam Mesylate.
As of Nov 16, 2026, ANDA 77826 (Fenoldopam Mesylate), held by Teva Parenteral, was first approved by FDA on Mar 7, 2007, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 7, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fenoldopam MesylateEQ 10MG BASE/ML ยท injectable;injection | Fenoldopam Mesylate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters